AMGN, Amgen Inc.

GLW, Corning Inc.

HRAL, HearAtLast Holdings Inc, HRAL.PK

DrStockPick Watch List!

DrStockPick Watch List! for Monday July 27, 2009

 

My Picks for Monday July 27, 2009 are:

**************************************************************

AMGN, Amgen Inc.

AMGN is a leading human therapeutics company in the biotechnology industry. For more than 25 years, the company has tapped the power of scientific discovery and innovation to advance the practice of medicine.

AMGN pioneered the development of novel products based on advances in recombinant DNA and molecular biology and launched the biotechnology industry’s first blockbuster medicines. Today, as a Fortune 500 company serving millions of patients, Amgen continues to

...

Hot IPOs Coming Your Way: Why Innovation Will Lead Our Recovery

by Louis Basenese, Advisory Panelist

Senior Analyst, The Oxford Club

Most folks have long since left the IPO market for dead… and it’s no wonder.

Scan the financial markets and very little - if anything - is consistently moving in a positive direction. And the latest economic data - unemployment, home foreclosures, bankruptcy filings, consumer spending - only underscores how far and wide this recession is cutting.

One thing, however, keeps chugging along, undeterred - innovation…

Innovation Will Lead The Economy’s Recovery

“Innovation goes up while the economy goes down,” says W. Chan Kim, Fellow of the World Economic Forum. And history suggests he’s not wrong. In 1969, while the economy slumped 1.9%, the number of patents granted jumped 14%.

During the energy-induced recession of the early 70s, unemployment hit 9%. GDP dropped 4.7%. And yet innovation handed us major breakthroughs

...

Sometime during the middle of the year, Genentech (DNA) shareholders are going to get $95 in cash for each share of Genentech stock they own. In total, nearly $47 billion in funds are expected to be returned to biotechnology investors.We've come up with an effective "basket approach" to re-deploy those funds back into the biotech sector -- in search of the next Genentech.Antisense Makes a Lot of SenseFor a little over $13, investors can pick up one share of Isis Pharmaceuticals (ISIS). Isis is the market leader in antisense technology.We've made it no secret in the past -- we are big fans of antisense. We view the drug discovery engine fueled by Isis' antisense technology very similar to the power of Genentech's recombinant DNA and monoclonal antibody technology breakthroughs of the 1980's. Antisense drugs are still in their infancy, ...